Independent report

Third primary COVID-19 vaccine dose for people who are immunosuppressed: JCVI advice

Statement from the Joint Committee on Vaccination and Immunisation (JCVI) on the benefits of a third primary COVID-19 vaccine dose in individuals aged 12 years and over with severe immunosuppression.

• From: Department of Health and Social Care
• Published: 1 September 2021

Documents

Joint Committee on Vaccination and Immunisation (JCVI) advice on third primary dose vaccination

HTML

Details

This statement sets out advice from the JCVI on the benefits of a third primary COVID-19 vaccine dose in individuals aged 12 years and over with severe immunosuppression around the time of their first or second vaccine doses.

See also:

• JCVI’s first statement on COVID-19 vaccination of children and young people aged 12 to 17 years, published in July 2021
• JCVI’s updated statement on COVID-19 vaccination of children and young people aged 12 to 17 years published in August 2021

Published 1 September 2021